TrovaGene, Inc. (NASDAQ: TROV) Starts Presentation at LD Micro 2017 Invitational
TrovaGene (NASDAQ: TROV) is a molecular diagnostic company that focuses on the development and commercialization of proprietary urine-based cell-free molecular diagnostic technology for use in disease detection and monitoring across various medical disciplines. The company intends to enhance the treatment outcomes for cancer patients through its proprietary technology to detect and quantitatively monitor cell-free DNA using urine or blood samples. It offers Precision Cancer Monitoring (PCM) platform, a cell-free molecular diagnostic platform that provides cancer monitoring by tracking and quantifying levels of cell-free DNA from either urine or blood samples. For more information, visit the company's website at www.trovagene.com. About…







